Dr Reddy's Labs plunges after US regulator issues three observations for company's Bachupally unit
Reddy's Laboratories Ltd (DRREDDY) shares plunged after the drug maker received three observations from the US drug maker for its Bachupally facility in Hyderabad.
Reddy's Laboratories Ltd (DRREDDY) shares tumbled on Monday after the company received three observations from the US Food and Drug Administration (FDA) for its research and development (R&D) unit located in Bachupally, Hyderabad. The drug maker's stock fell by as much as Rs 391.8, or 6.8 per cent, to Rs 5,371.8 apiece on BSE.
The US drug regulator conducted a pre-approval good manufacturing practices (GMP) inspection at the Hyderabad-based pharmaceutical company from December 4 to December 8, according to a regulatory filing.
"We have been issued a Form 483 with three observations, which we will address within the stipulated timeline," Dr Reddy's Labs said on Friday after the completion of the inspection by the FDA.
The fresh issues raised by the FDA mean more trouble for the Indian drug maker following 10 observations made by the regulator at the company's formulation manufacturing unit in the same location.
In October, the US drug regulator had made 10 observations at the company's formulation manufacturing facility in Bahupally after carrying out an inspection from October 10 to October 27.
According to Zee Business research, details of the 10 issues raised by the US Food and Drug Administration about the Bachupally unit of Dr Reddy's are serious and could prompt the US health regulator to issue a warning letter to the company. The issues raised by the regulator include microbial contamination, data integrity and market complaints, the Zee Business analysts pointed out.
Dr Reddy's Labs manufactures more than 100 products at the Bachuplly unit, which accounts for 30 per cent of the company's overall revenue from the US market, according to brokerages.
Four out of the company's top 10 products are manufactured at the facility, according to Zee Business research.
(This story will be updated shortly)
Catch the latest stock market updates here. For all other news related to business, politics, tech, sports and auto, visit Zeebiz.com.
Get Latest Business News, Stock Market Updates and Videos; Check your tax outgo through Income Tax Calculator and save money through our Personal Finance coverage. Check Business Breaking News Live on Zee Business Twitter and Facebook. Subscribe on YouTube.
RECOMMENDED STORIES
Retirement Planning: SIP+SWP combination; Rs 15,000 monthly SIP for 25 years and then Rs 1,52,000 monthly income for 30 years
Top Gold ETF vs Top Large Cap Mutual Fund 10-year Return Calculator: Which has given higher return on Rs 11 lakh investment; see calculations
Retirement Calculator: 40 years of age, Rs 50,000 monthly expenses; what should be retirement corpus and monthly investment
SBI 444-day FD vs Union Bank of India 333-day FD: Know maturity amount on Rs 4 lakh and Rs 8 lakh investments for general and senior citizens
EPF vs SIP vs PPF Calculator: Rs 12,000 monthly investment for 30 years; which can create highest retirement corpus
Home loan EMI vs Mutual Fund SIP Calculator: Rs 70 lakh home loan EMI for 20 years or SIP equal to EMI for 10 years; which can be easier route to buy home; know maths
01:16 PM IST